[1]张伟娜,黄晓华.多西他赛联合洛铂腹腔灌注治疗晚期卵巢癌患者的临床疗效评价[J].医学信息,2019,32(08):154-155158.[doi:10.3969/j.issn.1006-1959.2019.08.047]
　ZHANG Wei-na,HUANG Xiao-hua.Clinical Evaluation of Docetaxel Combined with Lobaplatin in the Treatment of Patients with Advanced Ovarian Cancer[J].Journal of Medical Information,2019,32(08):154-155158.[doi:10.3969/j.issn.1006-1959.2019.08.047]
点击复制

多西他赛联合洛铂腹腔灌注治疗晚期卵巢癌患者的临床疗效评价()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
32卷
期数:
2019年08期
页码:
154-155158
栏目:
药物与临床
出版日期:
2019-04-15

文章信息/Info

Title:
Clinical Evaluation of Docetaxel Combined with Lobaplatin in the Treatment of Patients with Advanced Ovarian Cancer
文章编号:
1006-1959（2019）08-0154-03
作者:
张伟娜1; 黄晓华2
（佳木斯市中心医院二部妇产科1，中医科2，黑龙江 佳木斯 154002）
Author(s):
ZHANG Wei-na1; HUANG Xiao-hua2
(Department of Obstetrics and Gynecology1,Department of Traditional Chinese Medicine2,Jiamusi Central Hospital,Jiamusi 154002,Heilongjiang,China)
关键词:
多西他赛; 洛铂; 腹腔灌注; 晚期卵巢癌
Keywords:
Docetaxel; Lobaplatin; Intraperitoneal perfusion; Advanced ovarian cancer
分类号:
R737.31
DOI:
10.3969/j.issn.1006-1959.2019.08.047
文献标志码:
A
摘要:
目的 探讨多西他赛联合洛铂腹腔灌注治疗晚期卵巢癌患者的临床疗效。方法 选取2017年4月~2018年4月我院收治的晚期卵巢癌患者中76例，随机分为观察组和对照组，每组38例。对照组仅接受多西他赛静脉化疗治疗，观察组接受多西他赛联合洛铂腹腔灌注治疗。对比两组临床疗效，并观察治疗后患者糖类多肽抗原（CA125）、血清人附睾分泌蛋白4（HE4）水平以及不良反应发生情况。结果 观察组治疗总有效率为97.37%，高于对照组的84.21%，差异具有统计学意义（P＜0.05）。观察组治疗后CA125水平为（31.19±14.28）kU/L、HE4水平为（93.71±23.69）pmol/L，均低于对照组的（49.86±17.52）kU/L、（158.62±31.47）pmol/L，差异具有统计学意义（P＜0.05）。观察组总不良反应发生率为13.16%，低于对照组的28.95%，差异具有统计学意义（P＜0.05）。结论 晚期卵巢癌患者接受多西他赛联合洛铂腹腔灌注治疗效果更为理想，极大的改善了各功能指标，降低了不良反应发生率，临床实用价值较高。
Abstract:
Objective To investigate the clinical efficacy of docetaxel combined with lobaplatin in the treatment of patients with advanced ovarian cancer. Methods 76 patients with advanced ovarian cancer admitted to our hospital from April 2017 to April 2018 were randomly divided into observation group and control group, 38 cases in each group. The control group received only docetaxel intravenous chemotherapy, and the observation group received docetaxel plus lobaplatin intraperitoneal perfusion. The clinical efficacy of the two groups was compared, and the levels of carbohydrate polypeptide (CA125), serum human epididymal secretory protein 4 (HE4) and adverse reactions were observed. Results The total effective rate of the observation group was 97.37%, which was higher than that of the control group 84.21%,the difference was statistically significant (P<0.05). The CA125 level of the observation group was (31.19±14.28) kU/L and the HE4 level was (93.71±23.69) pmol/L, which was lower than that of the control group (49.86±17.52) kU/L, (158.62±31.47) pmol/L, the difference was statistically significant (P<0.05). The incidence of total adverse reactions was 13.16% in the observation group, which was lower than that in the control group 28.95%,the difference was statistically significant (P<0.05). Conclusion The treatment of patients with advanced ovarian cancer with docetaxel combined with lobaplatin is more ideal, which greatly improves the functional indicators, reduces the incidence of adverse reactions, and has higher clinical value.

参考文献/References:

[1]王爱红,赵菊梅,杜娟,等.腹腔热灌注化疗联合腹部射频热疗对老年晚期卵巢癌患者的疗效分析[J].中国免疫学杂志,2018,34(4):583-588. [2]姚世惠,何丽萍,杨英捷.化疗联合顺铂腹腔热灌注在卵巢癌术后治疗中的应用效果评定[J].医药前沿,2017,7(6):117-118. [3]Kim JW,Choi SH.Re:Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy with lobaplatin and docetaxel to treat synchronous peritoneal carcinomatosis from gastric cancer: Results from a Chinese center, Eur J Surg Oncol (2016)[J].Eur J Surg Oncol,2016,42(11):1760-1761. [4]段树锋.多西他赛、腹腔热灌注化疗联合热疗治疗晚期卵巢癌的疗效及安全性评价[J].医学理论与实践,2017,30(24):3683-3684. [5]周国成.顺铂腹腔灌注联合多西他赛静脉化疗方案在晚期卵巢癌患者中的应用效果比较[J].癌症进展,2016,14(3):280-282.

相似文献/References:

[1]朱淑娟.多西他赛在控制晚期非小细胞肺癌恶性胸腔积液的 疗效和安全性评估[J].医学信息,2018,31(15):132.[doi:10.3969/j.issn.1006-1959.2018.15.042]
　ZHU Shu-juan.Efficacy and Safety of Docetaxel in the Control of Malignant Pleural Effusion in Patients with Advanced Non-small Cell Lung Cancer[J].Journal of Medical Information,2018,31(08):132.[doi:10.3969/j.issn.1006-1959.2018.15.042]
[2]张晓玲.替吉奥联合多西他赛治疗转移性乳腺癌的临床疗效观察[J].医学信息,2018,31(20):128.[doi:10.3969/j.issn.1006-1959.2018.20.038]
　ZHANG Xiao-ling.Clinical Observation of Tegafur,Gimeracil and Oteracil Porassium Capsules Combined with Docetaxel in the Treatment of Metastatic Breast Cancer[J].Journal of Medical Information,2018,31(08):128.[doi:10.3969/j.issn.1006-1959.2018.20.038]
[3]苏 志,吴 蔚,吴智钢,等.含洛铂方案新辅助化疗结合保肢手术治疗骨肉瘤的临床疗效观察[J].医学信息,2018,31(21):83.[doi:10.3969/j.issn.1006-1959.2018.21.022]
　SU Zhi,WU Wei,WU Zhi-gang,et al.Clinical Efficacy of Neoadjuvant Chemotherapy with Lobaplatin Combined with Limb Salvage Surgery for OsteosarcomaC[J].Journal of Medical Information,2018,31(08):83.[doi:10.3969/j.issn.1006-1959.2018.21.022]
[4]刘 鑫,张劲松,王海峰.转移性激素敏感性前列腺癌研究进展[J].医学信息,2019,32(15):30.[doi:10.3969/j.issn.1006-1959.2019.15.011]
　LIU Xin,ZHANG Jin-song,WANG Hai-feng.Research Progress on the Metastatic Hormone-sensitive Prostate Cancer[J].Journal of Medical Information,2019,32(08):30.[doi:10.3969/j.issn.1006-1959.2019.15.011]
[5]任勇军,闵旭立,徐 浩,等.洛铂联合表柔比星化疗栓塞治疗原发性肝细胞癌的疗效[J].医学信息,2019,32(24):43.[doi:10.3969/j.issn.1006-1959.2019.24.014]
　REN Yong-jun,MIN Xu-li,XU Hao,et al.Efficacy of Loplatin Combined with Epirubicin Chemotherapy and Embolization for Primary Hepatocellular Carcinoma[J].Journal of Medical Information,2019,32(08):43.[doi:10.3969/j.issn.1006-1959.2019.24.014]
[6]付大鹏.多西他赛联合表柔比星新辅助化疗治疗乳腺癌的效果[J].医学信息,2020,33(05):149.[doi:10.3969/j.issn.1006-1959.2020.04.048]
　FU Da-peng.Evaluation of Docetaxel Combined with Epirubicin Neoadjuvant Chemotherapy for Breast Cancer[J].Journal of Medical Information,2020,33(08):149.[doi:10.3969/j.issn.1006-1959.2020.04.048]
[7]葛文军,宋继荣.紫杉醇联合洛铂在局部晚期宫颈癌患者术前新辅助化疗中的应用[J].医学信息,2020,33(13):106.[doi:10.3969/j.issn.1006-1959.2020.13.029]
　GE Wen-jun,SONG Ji-rong.Paclitaxel Combined with Lobaplatin in Neoadjuvant Chemotherapy for Patients with Locally Advanced Cervical Cancer[J].Journal of Medical Information,2020,33(08):106.[doi:10.3969/j.issn.1006-1959.2020.13.029]
[8]杨 欢,朱 梅,张改琴,等.多西他赛腹腔灌注加静脉化疗及口服替吉奥联合阿帕替尼治疗胃癌腹膜转移患者的效果[J].医学信息,2022,35(19):121.[doi:10.3969/j.issn.1006-1959.2022.19.034]
　YANG Huan,ZHU Mei,ZHANG Gai-qin,et al.Effect of Docetaxel Intraperitoneal Perfusion Plus Intravenous Chemotherapy and Oral Tegafur Combined with Apatinib in the Treatment of Gastric Cancer Patients with Peritoneal Metastasis[J].Journal of Medical Information,2022,35(08):121.[doi:10.3969/j.issn.1006-1959.2022.19.034]
[9]王启平,兰安宁,吴晓峰.低剂量地塞米松对乳腺癌化疗不良反应的影响[J].医学信息,2020,33(14):146.[doi:10.3969/j.issn.1006-1959.2020.14.045]
　WANG Qi-ping,LAN An-ning,WU Xiao-feng.Effect of Low-dose Dexamethasone on Adverse Reactions of Chemotherapy in Breast Cancer[J].Journal of Medical Information,2020,33(08):146.[doi:10.3969/j.issn.1006-1959.2020.14.045]
[10]刘志坚,刘海燕,宿抱玉.阿帕替尼联合多西他赛治疗晚期非小细胞肺癌疗效和安全性的Meta分析[J].医学信息,2021,34(07):10.[doi:10.3969/j.issn.1006-1959.2021.07.003]
　LIU Zhi-jian,LIU Hai-yan,SU Bao-yu.Meta-analysis of the Efficacy and Safety of Apatinib Combined with Docetaxel in the Treatment of Advanced Non-small Cell Lung Cancer[J].Journal of Medical Information,2021,34(08):10.[doi:10.3969/j.issn.1006-1959.2021.07.003]

更新日期/Last Update: 2019-04-15